The company has received approval from the United States Food and Drug Administration (USFDA) to market its emtricitabine and tenofovir disoproxil fumarate tablets, 200 mg/300 mg, Lupin said in a regulatory filing.
The combination of Emtricitabine and Tenofovir slows down the spread of HIV in the body and is used along with other medications to treat HIV in adults and children.